WAP
FLNA

Wealthcare Advisory Partners’s Filana Therapeutics FLNA Stock Holding History

Wealthcare Advisory Partners’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10
Closed – – 1619
2021
Q1 		$0 Buy
+10
New +$393 ﹤0.01% 2102

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wealthcare Advisory Partners's FLNA Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Filana Therapeutics (FLNA) in Q2 2021, closing a stake of 10 shares.

Wealthcare Advisory Partners first reported a position in FLNA in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 169 funds tracked by Wall St. Rank hold FLNA as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining Filana Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 10 Filana Therapeutics shares in Q2 2021.
  • Wealthcare Advisory Partners first reported a position in Filana Therapeutics in Q1 2021 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Filana Therapeutics position peaked at $0 in Q1 2021.
  • 169 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.